Ligand-targeted liposome

Add links
From Wikipedia, the free encyclopedia
Representative image of the constituents of a basic liposome.

A ligand-targeted liposome (LTL) is a nanocarrier with specific ligands attached to its surface to enhance localization for targeted drug delivery. The targeting ability of LTLs enhances cellular localization and uptake of these liposomes for therapeutic or diagnostic purposes. LTLs have the potential to enhance drug delivery by decreasing peripheral systemic toxicity, increasing in vivo drug stability, enhancing cellular uptake, and increasing efficiency for chemotherapeutics and other applications. Liposomes are beneficial in therapeutic manufacturing because of low batch-to-batch variability, easy synthesis, favorable scalability, and strong biocompatibility. Ligand-targeting technology enhances liposomes by adding targeting properties for directed drug delivery.[1]

Ligand selection[edit]

Ligands are molecules responsible for binding to receptors in the cellular targeting process. Surface-coupled ligands offer a greater degree of freedom to move on the liposome membrane for optimal interactions.[2] Ligands are typically monoclonal antibodies (mAbs) or antibody fragments, but can also include other molecules such as ARPG,[3] proteins, peptides, vitamins, carbohydrates, and glycoproteins.[1] The choice of ligand can significantly influence the behavioral and functional properties of a ligand-targeted liposome. Antibody fragments have lower immunogenicity and improved pharmacokinetics.[citation needed] mAbs are unique and can be used for inhibition of DNA repair, terminating the cell cycle, and triggering apoptosis, all of which factor into applications for anticancer drugs.[4] Peptides are relatively easy and affordable to prepare with low antigenicity and lower opsonization which are more resistant to enzymatic degradation. Proteins can target the transferrin receptor membrane glycoprotein. Sugars and vitamins are recognized by cellular transport receptors.[1] Ligand choice is based on receptor expression, ligand internalization, binding affinity, and type of ligand.[citation needed] Ligands alone are not able to carry an efficient payload for therapeutic levels but can carry more of the agent when combined with liposomes.[2]

Ligand attachment to liposome[edit]

Liposomes can be functionalized with long-chain, high density brush regime PEG, a then a ligand binds to the PEG chain resulting in an LTL.

Ligands can be attached to liposomes through ligation to create ligand-targeted liposomes in a variety of ways. Liposomes have a lipid outer layer that can be used to bind ligands. Conjugation of the ligand to the surface of a liposome can be achieved through multiple routes. Covalent binding[5][6] is a prominent way due to the anchoring between the long-chain fatty acids and the ligand. Combinations of covalent binding through disulfide linkages,[7] heating,[8] and hydrophobic interactions[9] can be used depending on the properties of the liposome and ligand. Adsorption and membrane fusion are non-covalent methods for the attachment of monoclonal antibodies.[10][2] Chemical linkages such as covalent bonds are more effective at increasing the amount of attached ligand to the carrier as opposed to non-covalent methods.[11] During chemical coupling for manufacturing, it is crucial that ligands maintain their integrity when attached to the liposome surface. If ligands, such as antibodies, do not maintain binding specificity, proper orientation, and coupling efficiency the liposome will not be effective.[2]

Cellular interaction and delivery of contained agent[edit]

Ligands specifically bind to target receptors and dock to the site of interest, which is a protein in this case.

The ligand chosen for the application depends on the target site selected and it is responsible for cellular interaction. The target site contains the binding sites that the ligands target to deliver the LTL to the desired area. Favorable target site characteristics are determined by what is commonly expressed by tissues of the pathology of interest. Determinants can include histones, basement membrane fibrinogen, selectins, adhesion molecules, or other ligand targets. For example, in some human cancer tumors such as ovarian carcinomas, folate is over-expressed. Ligand-targeted liposomes for targeting cancer often use this over-expression of folate and a ligand that targets this vitamin to localize drug delivery to the desired area.[12][2] Ligand-targeted liposomes utilize active targeting to interact with the desired cells.[11]

There are three ways in which liposomes can enter the cellular membrane. (a) phagocytosis (b) pinocytosis (c) receptor-mediated endocytosis

Once administered intravenously into blood circulation, ligand-targeted liposomes must travel to reach the target area to deliver their contents. LTLs retain the contained agent until the process of cellular uptake. LTLs are taken into cells through the process of receptor-mediated endocytosis.[citation needed] The ligand chosen for each application also depends on the target site selected. The target site contains the binding sites that the ligands target to deliver the LTL to the desired area. In some human tumors such as ovarian carcinomas, folate is over-expressed. Ligand-targeted liposomes for use in this application use this over-expression to folate and a ligand that targets folate to localize drug delivery to the desired area.[2] The tumor microenvironment of solid tumor cancers is also a unique targeting site. Tumor endothelial cells are important for angiogenesis which is key to tumor growth, therefore using LTLs to target these cells can limit the growth and vascularization of a tumor.[3]

Receptor-mediated endocytosis is the most common way LTLs deliver material to the cell. The targeting ligand attached to the liposome attaches to the binding site found on the cell of interest. The particles are transported to lysosomes to be processed. This process allows the molecules to cross the blood-brain barrier, which allows the drug to be delivered to tissue that is relatively difficult to reach without a specific mechanism. Less commonly, pinocytosis or phagocytosis may be used for cellular uptake of the liposome.[12] Certain recognition sites, such as ecto-NAD+oglycohydro|ase, mediate uptake to aid in the internalization and effectiveness of the LTLs.[13]

The remainder of LTLs in circulation after binding to the target site are mainly cleared through the reticuloendothelial system (RES). The RES includes different organs including the kidneys, lungs, spleen, liver, bone marrow, and lymph nodes. The liver is the primary organ for the clearance of LTLs. The RES is most likely able to clear LTLS due to fenestrations in their microvasculature that allow for extravasation. Phagocytic cells within the RES break down LTLs.[14]

LTLs can be loaded with an imaging agent and injected to specifically bind to desired tissue, such as a tumor.

Applications of LTLs in Medicine[edit]

Ligand-targeted liposomes are used for a variety of applications depending on the liposome, ligand, and liposome contents. Ligand-targeted liposomes can also be used for diagnostics through imaging. The liposomes can contain imaging agents to aid in visualization such as fluorescent dyes, labeling probes, and contrast agents.[15] Commonly, a radioactive gamma-emitter, fluorescent marker, or magnetic resonance imaging (MRI) agent is encapsulated in the liposome for this application.[2] The active targeting mechanism of LTLs allows the target tissue to retain the imaging agent while the remaining agent is cleared from circulation. The ligand-targeted liposomes increase the specificity and sensitivity of the images taken through positron emission tomography (PET), single-photon emission computed tomography (SPECT), and MRI techniques through the ligand localization to receptors of interest.[15] Biotinylated liposomes containing [67Ga] coupled with a later injection of avidin have been shown to reduce background signal and produce the needed contrast for imaging while reducing the circulation time of radioactive imaging agent.[16] Molecular imaging of processes over time in vivo is also made possible using ligand-targeted nanoparticles.[17] As of 2015, many ligand-targeted imaging agents such as MIP-1404, MIP-1405, MIP-1072, MIP-109, and 18F-DCFBC were undergoing clinical trials. The ability of a liposome to encapsulate these imaging agents and deliver them to specific regions through ligand targeting is helpful for precision detection.[18]

Ligand-targeted liposomes are a promising method of drug delivery. These systems are efficient in delivering the drug to localized areas with low peripheral distribution, which minimizes the off-target effects. The favorable biodistribution to target tissue is an encouraging property of this drug delivery system. In addition to highly targeting tissue, the ligand-targeted liposomes have a short circulating half-life, so they can be quickly cleared from the bloodstream.[2][19] Ligand-targeted liposomes can be used to deliver AuNRs for localized delivery of photo-thermal therapy in cancer treatment.[20] Photodynamic therapy (PDT) is a non-invasive cancer therapy that relies on a photosensitizing (PS) pro-drug to interact with light and oxygen as a cancer therapeutic agent. PSs can be encapsulated in LTLs, allowing them to move through systemic circulation to the tumor site for ligand binding to specify the area of their effect. Using PDT causes damage to cancer cells and tumor microvasculature.[3] There are many liposome-based products currently approved or undergoing clinical trials.

Aside from cancer therapies, ligand-targeted liposomes can also be used to target inflammation in the body that may be present due to rheumatoid arthritis, psoriasis, vascular inflammation, and organ transplantation. E-selectin is a cell-specific receptor expressed by inflamed endothelium that ligands can target.[21]

LTLs also have the potential for localized treatment in fungal infections.[21] AmBisome (L-AMB) is an LTL that contains Amphotericin B (AMPH-B), an anti-fungal treatment that is effective for a broad variety of fungal infections. AMPH-B can be toxic after prolonged exposure, making it a good candidate for the targeting and rapid clearing of systemic circulation of LTLs. AmBisome is also effective due to the inflammation in the area of fungal activity, which increases vascular permeation.[22]

Marketed Liposomes[23]
Cancer Therapy Fungal Diseases Analgesics Photodynamic

Therapy

Viral Vaccines
Doxil DaunoXome Abelect DepoDur Visudyne Epaxal
Depocyt Mepact Abmisome
Marqibo Myocet Amphotec Exparel Inflexal V
Onivyde

Disadvantages[edit]

Consistently producing ligand-targeted liposomes through traditional methods is difficult. The process can be tedious, challenging to control and result in a poorly defined system. Using the ‘post-insertion’ technique that involves micelles formed from PEG-linked ligands incubated with pre-formed, drug-loaded, non-targeted liposomes and they combine to form LTLs can limit the associated manufacturing challenges.[citation needed]

When using certain ligands, such as antibodies, the risk for an immunological reaction poses a risk. Liposome design including size, charge, morphology, composition, surface characteristics, and dose size can all influence the immune response to administered LTLs.[14] The ligands used can elicit an immune response when introduced into the body. For example, when peptide ligands such as CDX are used for brain-targeted delivery systems, they are immunogenic and trigger an immune response.[24] Complement Activation-Related Pseudo-allergies (CARPA) is a hypersensitivity syndrome that can be triggered when LTLs activate the innate immune system and the complement system. CARPA can cause many side effects including anaphylaxis, cardiopulmonary distress, and facial swelling. These side effects have the potential to be severe, which generates concern when administering LTLs to patients with health problems, especially cardiovascular issues. This reaction can be reduced by slowing infusion rates or incorporating the use of allergy medicines like antihistamines into the treatment regimen.[14]

Due to the immune response, LTLs can experience the accelerated blood clearance (ABC) phenomenon. This phenomenon is more common in repeated dosage usage of LTLs, such as multi-dose PEGylated formulas, because of immunological memory. The pharmokinetics and clearance rates of the second dose have been shown to be significantly reduced while accumulation in the spleen and liver increases. This poses challenges for clinical applications of LTLs that require multiple doses to be effective.[14]

Ligand-targeted liposomes need specific conditions to remain intact for use. Controlling environmental factors such as temperature and pH is necessary to maintain the integrity of the molecules. This can be helpful for temperature-sensitive or pH-dependent drug release conditions but is harmful if the pH changes at an inopportune time.[25] This technology can also be used in combination with enzymes such as in Gal-Dox, which releases active doxorubicin in combination with β-Galactosidase.[26] Making sure the compound does not encounter the enzyme too early is also important for effective usage.

There is a possibility that LTLs lead to immunosuppression. LTLs are cleared through the RES which is part of the innate immune system. Macrophage saturation to remove the liposomes could impact the ability of the phagocytic cells to function properly to conduct immune functions. Significant immune suppression has not been observed in clinical cases for therapeutic doses of LTLs containing non-cytotoxic drugs.[14]

References[edit]

  1. ^ a b c Noble, Gavin; Stefanick, Jared; Ashley, Johnathan; Kiziltepe, Tanyel; Bilgicer, Basar (January 2014). "Ligand-targeted liposome design: challenges and fundamental considerations". Trends in Biotechnology. 32 (1): 32–45. doi:10.1016/j.tibtech.2013.09.007. PMID 24210498.
  2. ^ a b c d e f g h Forssen, Eric; Willis, Michael (February 1998). "Ligand-targeted liposomes". Advanced Drug Delivery Reviews. 29 (3): 249–271. doi:10.1016/S0169-409X(97)00083-5. PMID 10837594.
  3. ^ a b c Gierlich, Piotr; Mata, Ana I.; Donohoe, Claire; Brito, Rui M. M.; Senge, Mathias O.; Gomes-da-Silva, Lígia C. (2020-11-14). "Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment". Molecules (Basel, Switzerland). 25 (22): 5317. doi:10.3390/molecules25225317. ISSN 1420-3049. PMC 7698280. PMID 33202648.
  4. ^ Sapra, P.; Allen, T.M. (2003). "Ligand-targeted liposomal anticancer drugs". Progress in Lipid Research. 42 (5): 439–462. doi:10.1016/S0163-7827(03)00032-8. PMID 12814645.
  5. ^ Nair, Pradeep; Flores, Heather; Gogineni, Alvin; Ashkenazi, Avi (March 2015). "Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display". PNAS. 112 (18): 5679–5684. Bibcode:2015PNAS..112.5679N. doi:10.1073/pnas.1418962112. PMC 4426393. PMID 25902490.
  6. ^ Crosasso, Paul; Brusa, Paola; Dosio, Franco; Arpicco, Silvia; Pacchioni, Donatella; Schuber, Francis; Cattel, Luigi (July 1997). "Antitumoral Activity of Liposomes and Immunoliposomes Containing 5-Fluorouridine Prodrugs". Journal of Pharmaceutical Sciences. 86 (7): 832–839. doi:10.1021/js9604467. PMID 9232525.
  7. ^ Leserman, L. D.; Barbet, J.; Kourilsky, F.; Weinstein, J. N. (1980-12-11). "Targeting to cells of fluorescent liposomes covalently coupled with a monoclonal antibody or protein A". Nature. 288 (5791): 602–604. Bibcode:1980Natur.288..602L. doi:10.1038/288602a0. ISSN 0028-0836. PMID 7442804. S2CID 4344687. Archived from the original on 2022-06-21. Retrieved 2023-04-15.
  8. ^ Weissmann, G.; Brand, A.; Franklin, E.C. (February 1974). "Interaction of immunoglobulins with liposomes". The Journal of Clinical Investigation. 53 (2): 536–543. doi:10.1172/JCI107587. PMC 301496. PMID 11344567.
  9. ^ Weissig, V.; Lasch, J.; Klibanov, A.L.; Torchilin, V.P. (June 1986). "A new hydrophobic anchor for the attachment of proteins to liposomal membranes". FEBS Letters. 202 (1): 86–90. doi:10.1016/0014-5793(86)80654-8. PMID 3720949. S2CID 28169963.
  10. ^ Blackwell, J E; Dagia, N M; Dickerson, J B; Berg, E L; D J, Goetz (June 2001). "Ligand coated nanosphere adhesion to E- and P-selectin under static and flow conditions". Annals of Biomedical Engineering. 29 (6): 523–533. doi:10.1114/1.1376697. PMID 11459346. S2CID 23722191.
  11. ^ a b Nobs, Leila; Buchegger, Franz; Gurny, Robert; Allémann, Eric (March 2004). "Current methods for attaching targeting ligands to liposomes and nanoparticles". Journal of Pharmaceutical Sciences. 93 (8): 1980–1992. doi:10.1002/jps.20098. PMID 15236448.
  12. ^ a b Muro, Silvia (December 2012). "Challenges in design and characterization of ligand-targeted drug delivery systems". Journal of Controlled Release. 164 (2): 125–137. doi:10.1016/j.jconrel.2012.05.052. PMC 3481020. PMID 22709588.
  13. ^ Salord, J.; Schuber, F. (September 1988). "In vitro drug delivery mediated by ecto-NAD+-glycohydrolase ligand-targeted liposomes". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 971 (2): 197–206. doi:10.1016/s0005-2728(88)80107-5. PMID 3167100.
  14. ^ a b c d e Sercombe, Lisa; Veerati, Tejaswi; Moheimani, Fatemeh; Wu, Sherry Y.; Sood, Anil K.; Hua, Susan (2015-12-01). "Advances and Challenges of Liposome Assisted Drug Delivery". Frontiers in Pharmacology. 6: 286. doi:10.3389/fphar.2015.00286. ISSN 1663-9812. PMC 4664963. PMID 26648870.
  15. ^ a b Lamichhane, Narottam; Udayakumar, Thirupandiyur; D'Souza, Warren; Simone II, Charles; Raghavan, Srinivasa; Polf, Jerimy; Mahmood, Javed (February 2018). "Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery". Molecules. 23 (2): 288. doi:10.3390/molecules23020288. PMC 6017282. PMID 29385755.
  16. ^ Ogihara-Umeda, I.; Sasaki, T.; Toyama, H.; Oda, K.; Senda, M.; Nishigori, H. (1994-01-15). "Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin". Cancer Research. 54 (2): 463–467. ISSN 0008-5472. PMID 8275482. Archived from the original on 2023-04-17. Retrieved 2023-04-15.
  17. ^ Lanza, Gregory; Abendschein, Dana; Hall, Christopher; Scott, Michael; Scherrer, David; Houseman, Andrew; Miller, James; Wickline, Samuel (June 2000). "In Vivo Molecular Imaging of Stretch-Induced Tissue Factor in Carotid Arteries with Ligand-Targeted Nanoparticles". Journal of the American Society of Echocardiography. 13 (6): 608–614. doi:10.1067/mje.2000.105840. PMID 10849515.
  18. ^ Srinivasarao, Madduri; Galliford, Chris; Low, Phillip (February 2015). "Principles in the design of ligand-targeted cancer therapeutics and imaging agents". Nature Reviews Drug Discovery. 14 (3): 203–219. doi:10.1038/nrd4519. PMID 25698644. S2CID 19704999.
  19. ^ Lin, Congcong; Zhang, Xue; Chen, Hubiao; Zhang, Ge; Riaz, Muhammad Kashif; Tyagi, Deependra; Lin, Ge; Zhang, Yanbo; Wang, Jinjin; Lu, Aiping; Yang, Zhijun (2018). "Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide". Drug Delivery. 25 (1): 256–266. doi:10.1080/10717544.2018.1425777. PMC 6058720. PMID 29334814. S2CID 23378139.
  20. ^ Nguyen, Van Du; Min, Hyun-Ki; Han, Jiwon; Park, Jong-Oh; Choi, Eunpyo (January 2019). "Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo". Colloids and Surfaces B: Biointerfaces. 173: 539–548. doi:10.1016/j.colsurfb.2018.10.013. PMID 30343218. S2CID 53026883.
  21. ^ a b van Alem, Carla; Metselaar, Josbert; van Kooten, Cees; Rotmans, Joris (July 2021). "Recent advances in liposomal-based anti-inflammatory therapy". Pharmaceutics. 13 (7): 1004. doi:10.3390/pharmaceutics13071004. PMC 8309101. PMID 34371695.
  22. ^ Takemoto, Koji; Kanazawa, Katsunori (September 2017). "AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy". Journal of Liposome Research. 27 (3): 186–194. doi:10.1080/08982104.2016.1205087. ISSN 1532-2394. PMID 27328721. S2CID 3308277. Archived from the original on 2023-04-17. Retrieved 2023-04-15.
  23. ^ Bulbake, Upendra; Doppalapudi, Sindhu; Kommineni, Nagavendra; Khan, Wahid (2017-03-27). "Liposomal Formulations in Clinical Use: An Updated Review". Pharmaceutics. 9 (2): 12. doi:10.3390/pharmaceutics9020012. ISSN 1999-4923. PMC 5489929. PMID 28346375.
  24. ^ Guan, Juan; Zhang, Zui; Jiang, Zhuxuan; Yang, Yang; Lou, Meiqing; Qian, Jun; Lu, Weiyue; Zhan, Changyou (July 2018). "Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption". Nature Communications. 9 (1): 2982. Bibcode:2018NatCo...9.2982G. doi:10.1038/s41467-018-05384-1. PMC 6065320. PMID 30061672.
  25. ^ Lee, Y.; Thompson, D.H. (February 2017). "Stimuli-Responsive Liposomes for Drug Delivery". WIREs Nanomedicine and Nanobiotechnology. 9 (5): 1450. doi:10.1002/wnan.1450. PMC 5557698. PMID 28198148.
  26. ^ Sharma, Amit; Kim, Eun-Joong; Shi, Hu; Lee, Jin Yong; Chung, Bong Geun; Kim, Jong Seung (February 2018). "Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation". Biomaterials. 155: 145–151. doi:10.1016/j.biomaterials.2017.11.019. PMID 29175083.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ligand-targeted_liposome&oldid=1191915923"